Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Common Stock
IMVT | US
26.41
USD-0.25
-0.94%
IMVT | US
About Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
26.41
Open
26.42
High
26.84
Low
25.04
Immunovant Inc. a clinical-stage biopharmaceutical company develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York New York. Immunovant Inc. is a subsidiary of Roivant Sciences Ltd.
View LessIMVT | US
Risk
27.0
Sharpe
0.54
Luna's Score
49/100
Recommendation
Hold
Luna says (IMVT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
25.8%1 month
27.0%3 months
44.8%6 months
53.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.86
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-14.12
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-298.26M
MarketCap
3.87B
MarketCap(USD)
3.87B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-64.55
Short ratio
11.04
Short perc.
19.76
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.21
Range1M
4.21
Range3M
6.92
Volumes: Market Activity
Rel. volume
1.06
Price X volume
32.61M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -14.12 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 44.82 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 3.87B | 3.66B | Par |
